ABCP: Atezolizumab/bevacizumab/carboplatin/paclitaxel
AC: Atypical carcinoid
ACP: Atezolizumab/carboplatin/paclitaxel
ACTH: Adrenocorticotropic hormone
ADC: Adenocarcinoma
AE: Adverse event
AIS: Adenocarcinoma in situ
AJCC: American Joint Committee on Cancer
ALK: Anaplastic lymphoma kinase
ALL: Acute lymphoblastic leukaemia
APC: Antigen-presenting cell
ASCO: American Society of Clinical Oncology
ATP: Adenosine triphosphate
BCP: Bevacizumab/carboplatin/paclitaxel
BID: Twice daily
BSC: Best supportive care
CAR: Chimeric antigen receptor
ChT: Chemotherapy
CI: Confidence interval
CIS: Carcinoma in situ
CISH: Chromogenic in situ hybridisation
CNS: Central nervous system
COPD: Chronic obstructive pulmonary disease
CRP: C-reactive protein
CRS: Cytokine release syndrome
CRT: Chemoradiotherapy
CT: Computed tomography
ctDNA: Circulating tumour DNA
CTLA-4: Cytotoxic T-lymphocyte antigen 4
DC: Dendritic cell
DCR: Disease control rate
DFS: Disease-free survival
DoR: Duration of response
EBUS: Endobronchial ultrsound
ECOG: Eastern Cooperative Oncology Group
EGF: Epidermal growth factor
EGFR: Epidermal growth factor receptor
EMT: Epithelial mesenchymal transition
EORTC: European Organisation for Research and Treatment of Cancer
EPP: Extrapleural pneumonectomy
ERCC1: Excision repair cross-complementation group 1
ES: Extensive stage
ETOP: European Thoracic Oncology Platform
EUS: Endoscopic ultrasound
EvG: Elastica van Gieson
FDA: Food & Drug Administration
FDG: Fluorodeoxyglucose
FGFR: Fibroblast growth factor receptor
FISH: Fluorescent in situ hybridisation
FNA: Fine needle aspiration
GGO: Ground glass opacity
GSP: General secretory pathway
HE: Haematoxylin–eosin
HER2: Human epidermal growth factor receptor 2
HIAA: Hydroxyindoleacetic acid
HR: Hazard ratio
IALT: International Adjuvant Lung Cancer Trial
IARC: International Agency for Research on Cancer
IASLC: International Association for the Study of Lung Cancer
ICI: Immune checkpoint inhibitor
IDO: Indoleamine 2,3-dioxygenase
IFN: Interferon
Ig: Immunoglobulin
IHC: Immunohistochemistry
IL: Interleukin
IMRT: Intensity modulated radiotherapy
IPD: Individual patient data
ISH: In situ hybridisation
ITT: Intention to treat
LACE: Lung Adjuvant Cisplatin Evaluation
LAG-3: Lymphocyte-activation gene 3
LAR: Long-acting release
LCNEC: Large cell neuroendocrine carcinoma
LDCT: Low-dose computed tomography
LINAC: Linear accelerator
LN: Lymph node
mAb: Monoclonal antibody
MEN-1: Multiple endocrine neoplasia type 1
MHC: Major histocompatibility complex
MKI: Multikinase inhibitor
MPE: Malignant pleural effusion
MPM: Malignant pleural mesothelioma
MRI: Magnetic resonance imaging
mTOR: Mammalian target of rapamycin
nAChR: Nicotinic acetylcholine receptor
NET: Neuroendocrine tumour
NGS: Next generation sequencing
NK: Natural killer
NLST: National Lung Screening Trial
NRT: Nicotine replacement therapy
NSCLC: Non-small cell lung cancer
NSE: Neuron-specific enolase
NSQ: Nonsquamous
NTRK: Neurotrophic tyrosine receptor kinase
ORR: Objective response rate / Overall response rate
OS: Overall survival
P/D: Pleurectomy/decortication
PAH: Polycyclic aromatic hydrocarbon
PAS: Periodic acid-Schiff
PCI: Prophylactic cranial irradiation
PCR: Polymerase chain reaction
PD-1/2: Programmed cell death protein 1/2
PDGFR: Platelet-derived growth factor receptor
PD-L1/2: Programmed death-ligand 1/2
PET: Positron emission tomography
PFS: Progression-free survival
PORT: Postoperative radiotherapy
PS: Performance status
QD: Once a day
qPCR: Quantitative polymerase chain reaction
RATS: Robotic-assisted thoracic surgery
RCT: Randomised clinical trial
RECIST: Response Evaluation Criteria in Solid Tumours
RR: Response rate
RT: Radiotherapy
SABR: Stereotactic ablative radiotherapy
SBM: Solitary brain metastasis
SCC: Squamous cell carcinoma
SCLC: Small cell lung cancer
SPN: Solitary pulmonary nodule
SQ: Squamous
SR: Sleeve resection
SST: Superior sulcus tumours
TBNA: Transbronchial needle aspiration
TC: Typical carcinoid
TCR: T cell receptor
T-DM1: Ado-trastuzumab emtansine
Teff: Effector T cell
TIM-3: T cell immunoglobulin and mucin domain 3
TKI: Tyrosine kinase inhibitor
TMB: Tumour mutation burden
TMD: Transmembrane domain
TNM: Tumour, Node, Metastasis
TPC: Tunnelled pleural catheter
TRK: Tropomyosin receptor kinase
TTF1: Thyroid transcription factor 1
TTP: Time to progression
UFT: Tegafur-uracil
UICC: Union for International Cancer Control
VATS: Video-assisted thoracoscopic surgery
VDT: Volume doubling time
VEGF: Vascular endothelial growth factor
VEGFR: Vascular endothelial growth factor receptor
WBRT: Whole brain radiotherapy
WHO: World Health Organization
